extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
fa65d8ca3c
commit
8ec691f5f2
7 changed files with 53 additions and 5 deletions
|
|
@ -119,6 +119,12 @@ International generic competition beginning January 2026 (Canada patent expiry,
|
|||
|
||||
If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits are comprehensively accounted for. The 'inflationary through 2035' conclusion appears to hold at the system level where costs and savings accrue to different entities, but inverts under risk-bearing payment models where the payer captures downstream savings. This suggests the cost impact is payment-structure-dependent, not inherent to the drug class.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -66,6 +66,12 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180
|
|||
|
||||
Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
10-year Medicare modeling quantifies the multi-organ value: 38,950 CV events avoided, $2,074/subject from CKD progression prevention, $1,512/subject from CV event avoidance. The compounding effect is measurable—T2D savings alone ($892M) exceed obesity costs ($205M) because the cardiovascular and renal benefits create value across multiple disease pathways simultaneously.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -46,6 +46,12 @@ SELECT trial economic model shows $2,074 per-subject lifetime savings from avoid
|
|||
|
||||
In the Medicare comprehensive model, CKD-related savings contribute $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year modeling window may underestimate dialysis delay value since ESRD costs accumulate over longer periods. MASH savings were only $28M system-wide, suggesting treatment costs don't accumulate enough in the 10-year window to produce large offsets despite clinical efficacy.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Medicare modeling quantifies CKD-specific savings at $2,074 per subject treated over 10 years. While smaller than T2D savings ($14,431/subject), the CKD benefit contributes meaningfully to net positive economics and demonstrates that kidney protection creates measurable financial value even within a 10-year window.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -43,6 +43,12 @@ The composition of spending shifts dramatically: less on chronic disease managem
|
|||
|
||||
The Medicare semaglutide analysis provides a boundary condition: when payment is integrated and multi-indication benefits compound, prevention CAN bend the cost curve down for specific payers. However, this requires: (1) single entity bearing costs and capturing savings, (2) multi-indication efficacy across high-cost conditions, (3) sufficient persistence to realize benefits. The system-level curve may still bend up while risk-bearing integrated payers see net savings—a payment structure divergence.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Semaglutide demonstrates the boundary condition: when a single payer bears both treatment costs and complication savings, the cost curve can bend DOWN rather than up. Medicare saves $715M over 10 years because the multi-indication benefits offset drug costs. This suggests the 'bends up through 2035' claim is payment-structure-dependent—true for fragmented FFS systems, potentially false for integrated risk-bearing models.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -59,6 +59,12 @@ CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by imp
|
|||
|
||||
CHW reimbursement infrastructure demonstrates the same payment boundary stall in the SDOH domain: 20 states with approved SPAs after 17 years, with billing code uptake remaining slow even where reimbursement is technically available. The bottleneck is not policy approval but operational infrastructure — CBOs cannot contract with healthcare entities, transportation costs are not covered, and 'community care hubs' are emerging as coordination infrastructure. This parallels VBC's 60% touch / 14% risk gap: technical capability exists but the operational infrastructure to execute at scale does not.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19*
|
||||
|
||||
Semaglutide economics provide concrete evidence for why full-risk arrangements matter: Medicare modeling shows net savings of $715M because the payer captures downstream CV, CKD, and T2D savings. Under partial-risk or FFS arrangements where drug costs and complication savings accrue to different entities, the same intervention appears cost-additive. This quantifies the value of crossing the payment boundary from partial to full risk.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -3,7 +3,8 @@
|
|||
{
|
||||
"filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
"missing_attribution_extractor",
|
||||
"opsec_internal_deal_terms"
|
||||
]
|
||||
}
|
||||
],
|
||||
|
|
@ -13,12 +14,13 @@
|
|||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:set_created:2026-03-18"
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:set_created:2026-03-19"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:missing_attribution_extractor"
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:missing_attribution_extractor",
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:opsec_internal_deal_terms"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
"date": "2026-03-19"
|
||||
}
|
||||
|
|
@ -7,13 +7,17 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-19
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,6 +49,18 @@ WHY ARCHIVED: This study provides the strongest evidence that the "inflationary
|
|||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare semaglutide modeling shows net savings of $715M over 10 years (range: $412M to $1.04B)
|
||||
- T2D-related impact: savings of ~$892 million over 10 years
|
||||
- Obesity-related impact: added costs of ~$205 million over 10 years
|
||||
- MASH-related impact: savings of ~$28 million over 10 years
|
||||
- 38,950 cardiovascular events avoided over 10 years with comprehensive semaglutide access
|
||||
- 6,180 deaths avoided (CV events + CKD/MASH progression)
|
||||
- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime treatment costs: $47,353
|
||||
- Savings from avoided T2D: $14,431/subject; avoided CKD: $2,074/subject; avoided CV events: $1,512/subject
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare semaglutide modeling shows net savings of $715M over 10 years (range: $412M to $1.04B)
|
||||
- T2D-related impact: savings of ~$892 million over 10 years
|
||||
|
|
|
|||
Loading…
Reference in a new issue